Publication Results

Generate Report

Add publications by marking their checkboxes, or

Targeting cholecystokinin-2 receptor for pancreatic cancer chemoprevention.

Mohammed A,  Janakiram NB,  Suen C,  Stratton N,  Lightfoot S,  Singh A,  Pathuri G,  Ritchie R,  Madka V,  Rao CV
Mol Carcinog 2019 Oct;58(10):1908-1918
Major Program(s) or Research Group(s): Chemopreventive Agent DevelopmentProstate and Urologic Cancer
PubMed ID: 31313401
PMC ID: PMC6721979 [available on October 01, 2020]

Evaluation of the STAT3 inhibitor GLG-302 for the prevention of estrogen receptor-positive and -negative mammary cancers.

Shoemaker RH,  Fox JT,  Juliana MM,  Moeinpour FL,  Grubbs CJ
Oncol Rep 2019 Sep;42(3):1205-1213
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 31322250
PMC ID: PMC6918811

Pharmacometabolomic Pathway Response of Effective Anticancer Agents on Different Diets in Rats with Induced Mammary Tumors.

Cao Z,  Miller MS,  Lubet RA,  Grubbs CJ,  Beger RD
Metabolites 2019 Jul 22;9(7)
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 31336604
PMC ID: PMC6680681

Corrigendum to "Proteomic characterization of outer membrane vesicles from gut mucosa-derived fusobacterium nucleatum". J Proteomics. 2019 Jan 8;195:125-137.

Liu J,  Hsieh CL,  Gelincik O,  Devolder B,  Sei S,  Zhang S,  Lipkin SM,  Chang YF
J Proteomics 2019 May 30;200:161
Major Program(s) or Research Group(s): Chemopreventive Agent Development ;  Office of the Director
PubMed ID: 30852158
PMC ID: not available

Optimized Bexarotene Aerosol Formulation Inhibits Major Subtypes of Lung Cancer in Mice.

Zhang Q,  Lee SB,  Chen X,  Stevenson ME,  Pan J,  Xiong D,  Zhou Y,  Miller MS,  Lubet RA,  Wang Y,  Mirza SP,  You M
Nano Lett 2019 Apr 10;19(4):2231-2242
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 30873838
PMC ID: not available

Exosomal miRNAs as Novel Pharmacodynamic Biomarkers for Cancer Chemopreventive Agent Early Stage Treatments in Chemically Induced Mouse Model of Lung Squamous Cell Carcinoma.

Zhou Y,  Zhang Q,  Du M,  Xiong D,  Wang Y,  Mohammed A,  Lubet RA,  Wang L,  You M
Cancers (Basel) 2019 Apr 4;11(4)
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 30987362
PMC ID: PMC6520832

Proteomic characterization of outer membrane vesicles from gut mucosa-derived fusobacterium nucleatum.

Liu J,  Hsieh CL,  Gelincik O,  Devolder B,  Sei S,  Zhang S,  Lipkin SM,  Chang YF
J Proteomics 2019 Mar 20;195:125-137
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 30634002
PMC ID: not available

Chemoprevention of Lung Carcinogenesis by Dietary Nicotinamide and Inhaled Budesonide.

Galbraith AR,  Seabloom DE,  Wuertz BR,  Antonides JD,  Steele VE,  Wattenberg LW,  Ondrey FG
Cancer Prev Res (Phila) 2019 Feb;12(2):69-78
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 30606719
PMC ID: not available

Comparison of Effects of Diet on Mammary Cancer: Efficacy of Various Preventive Agents and Metabolomic Changes of Different Diets and Agents.

Lubet RA,  Beger RD,  Miller MS,  Luster J,  Seifried HE,  Grubbs CJ
Cancer Prev Res (Phila) 2018 Dec;11(12):831-840
Major Program(s) or Research Group(s): Chemopreventive Agent DevelopmentNutritional Science
PubMed ID: 30459210
PMC ID: not available

Screening of Chemopreventive Agents in Animal Models: Results on Reproducibility, Agents of a Given Class, and Agents Tested During Tumor Progression.

Lubet RA,  Steele VE,  Shoemaker RH,  Grubbs CJ
Cancer Prev Res (Phila) 2018 Oct;11(10):595-606
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 30045934
PMC ID: PMC6186395

Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide.

Oerlemans R,  Berkers CR,  Assaraf YG,  Scheffer GL,  Peters GJ,  Verbrugge SE,  Cloos J,  Slootstra J,  Meloen RH,  Shoemaker RH,  Dijkmans BAC,  Scheper RJ,  Ovaa H,  Jansen G
Invest New Drugs 2018 Oct;36(5):797-809
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 29442210
PMC ID: PMC6153520

Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKt inhibitor MK2206 in mammary cancer models.

Lubet RA,  Steele VE,  Juliana MM,  Bode A,  Moeinpour F,  Grubbs CJ
Oncol Rep 2018 Sep;40(3):1545-1553
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 29565450
PMC ID: PMC6072405

Clinically Relevant Anti-Inflammatory Agents for Chemoprevention of Colorectal Cancer: New Perspectives.

Mohammed A,  Yarla NS,  Madka V,  Rao CV
Int J Mol Sci 2018 Aug 8;19(8)
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 30096840
PMC ID: PMC6121559

Airway brushing as a new experimental methodology to detect airway gene expression signatures in mouse lung squamous cell carcinoma.

Pan J,  Xiong D,  Zhang Q,  Szabo E,  Miller MS,  Lubet RA,  Wang Y,  You M
Sci Rep 2018 Jun 11;8(1):8895
Major Program(s) or Research Group(s): Chemopreventive Agent DevelopmentLung and Upper Aerodigestive Cancer
PubMed ID: 29891994
PMC ID: PMC5995924

Novel mutational landscapes and expression signatures of lung squamous cell carcinoma.

Xiong D,  Pan J,  Yin Y,  Jiang H,  Szabo E,  Lubet RA,  Wang Y,  You M
Oncotarget 2018 Jan 26;9(7):7424-7441
Major Program(s) or Research Group(s): Chemopreventive Agent DevelopmentLung and Upper Aerodigestive Cancer
PubMed ID: 29484121
PMC ID: PMC5800913

Current Challenges and Opportunities for Chemoprevention of Pancreatic Cancer.

Mohammed A,  Janakiram NB,  Madka V,  Li M,  Asch AS,  Rao CV
Curr Med Chem 2018;25(22):2535-2544
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 28183260
PMC ID: not available

Pancreatic Cancer Chemoprevention: Challenges and Opportunities.

Mohammed A,  Rao CV
Curr Med Chem 2018;25(22):2532-2534
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 30014794
PMC ID: not available

Effects of talactoferrin alpha on lung adenoma prevention in A/J mice June 2, 2016.

Seabloom DE,  Galbraith AR,  Haynes AM,  Fujita AS,  Antonides JD,  Wuertz BR,  Steele VE,  Ondrey FG,  Wattenberg LW
Am J Transl Res 2018;10(3):875-880
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 29636877
PMC ID: PMC5883128

Lack of chemopreventive effects of P2X7R inhibitors against pancreatic cancer.

Mohammed A,  Janakiram NB,  Madka V,  Pathuri G,  Li Q,  Ritchie R,  Biddick L,  Kutche H,  Zhang Y,  Singh A,  Gali H,  Lightfoot S,  Steele VE,  Suen CS,  Rao CV
Oncotarget 2017 Nov 17;8(58):97822-97834
Major Program(s) or Research Group(s): Chemopreventive Agent DevelopmentProstate and Urologic Cancer
PubMed ID: 29228654
PMC ID: PMC5716694

Targeting "Retired Antigens" for Cancer Immunoprevention.

Shoemaker RH,  Forsthuber TG
Cancer Prev Res (Phila) 2017 Nov;10(11):607-608
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 29093010
PMC ID: not available

Early and late effects of aspirin and naproxen on microRNAs in the lung and blood of mice, either unexposed or exposed to cigarette smoke.

Izzotti A,  Balansky R,  Ganchev G,  Iltcheva M,  Longobardi M,  Pulliero A,  Camoirano A,  D'Agostini F,  Geretto M,  Micale RT,  La Maestra S,  Miller MS,  Steele VE,  De Flora S
Oncotarget 2017 Oct 17;8(49):85716-85748
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 29156752
PMC ID: PMC5689642

Immunoprevention of KRAS-driven lung adenocarcinoma by a multipeptide vaccine.

Pan J,  Zhang Q,  Sei S,  Shoemaker RH,  Lubet RA,  Wang Y,  You M
Oncotarget 2017 Oct 10;8(47):82689-82699
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 29137294
PMC ID: PMC5669920

Effect of weekly or daily dosing regimen of Gefitinib in mouse models of lung cancer.

Zhang Q,  Li R,  Chen X,  Lee SB,  Pan J,  Xiong D,  Hu J,  Miller MS,  Szabo E,  Lubet RA,  Wang Y,  You M
Oncotarget 2017 Sep 22;8(42):72447-72456
Major Program(s) or Research Group(s): Chemopreventive Agent DevelopmentLung and Upper Aerodigestive Cancer
PubMed ID: 29069801
PMC ID: PMC5641144

Loss of natural killer T cells promotes pancreatic cancer in LSL-KrasG12D/+ mice.

Janakiram NB,  Mohammed A,  Bryant T,  Ritchie R,  Stratton N,  Jackson L,  Lightfoot S,  Benbrook DM,  Asch AS,  Lang ML,  Rao CV
Immunology 2017 Sep;152(1):36-51
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 28419443
PMC ID: PMC5543460

Lack of chemopreventive efficacy of metformin in rodent models of urinary bladder, head and neck, and colon/intestine cancer.

Thompson MD,  Lubet RA,  Mccormick DL,  Clapper ML,  Bode AM,  Juliana MM,  Moeinpour F,  Grubbs CJ
Oncol Lett 2017 Sep;14(3):3480-3486
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 28927103
PMC ID: PMC5587978

Pioglitazone-mediated reversal of elevated glucose metabolism in the airway epithelium of mouse lung adenocarcinomas.

Xiong D,  Pan J,  Zhang Q,  Szabo E,  Miller MS,  Lubet RA,  Wang Y,  You M
JCI Insight 2017 Jul 6;2(13)
Major Program(s) or Research Group(s): Chemopreventive Agent DevelopmentLung and Upper Aerodigestive Cancer
PubMed ID: 28679956
PMC ID: PMC5499364

Identification of a nucleoside analog active against adenosine kinase-expressing plasma cell malignancies.

Nayar U,  Sadek J,  Reichel J,  Hernandez-Hopkins D,  Akar G,  Barelli PJ,  Sahai MA,  Zhou H,  Totonchy J,  Jayabalan D,  Niesvizky R,  Guasparri I,  Hassane D,  Liu Y,  Sei S,  Shoemaker RH,  Warren JD,  Elemento O,  Kaye KM,  Cesarman E
J Clin Invest 2017 Jun 1;127(6):2066-2080
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 28504647
PMC ID: PMC5451239

Identification and characterization of enhancer agonist human cytotoxic T-cell epitopes of the human papillomavirus type 16 (HPV16) E6/E7.

Tsang KY,  Fantini M,  Fernando RI,  Palena C,  David JM,  Hodge JW,  Gabitzsch ES,  Jones FR,  Schlom J
Vaccine 2017 May 2;35(19):2605-2611
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 28389098
PMC ID: PMC5444324

Selenomethionine and methyl selenocysteine: multiple-dose pharmacokinetics in selenium-replete men.

Marshall JR,  Burk RF,  Payne Ondracek R,  Hill KE,  Perloff M,  Davis W,  Pili R,  George S,  Bergan R
Oncotarget 2017 Apr 18;8(16):26312-26322
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 28412747
PMC ID: PMC5432259

Bronchial airway gene expression signatures in mouse lung squamous cell carcinoma and their modulation by cancer chemopreventive agents.

Xiong D,  Pan J,  Zhang Q,  Szabo E,  Miller MS,  Lubet RA,  You M,  Wang Y
Oncotarget 2017 Mar 21;8(12):18885-18900
Major Program(s) or Research Group(s): Chemopreventive Agent DevelopmentLung and Upper Aerodigestive Cancer
PubMed ID: 27935865
PMC ID: PMC5386655

Fixed-Dose Combinations of Pioglitazone and Metformin for Lung Cancer Prevention.

Seabloom DE,  Galbraith AR,  Haynes AM,  Antonides JD,  Wuertz BR,  Miller WA,  Miller KA,  Steele VE,  Miller MS,  Clapper ML,  O'Sullivan MG,  Ondrey FG
Cancer Prev Res (Phila) 2017 Feb;10(2):116-123
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 28052934
PMC ID: PMC5690483

Safety and Preclinical Efficacy of Aerosol Pioglitazone on Lung Adenoma Prevention in A/J Mice.

Seabloom DE,  Galbraith AR,  Haynes AM,  Antonides JD,  Wuertz BR,  Miller WA,  Miller KA,  Steele VE,  Suen CS,  O'Sullivan MG,  Ondrey FG
Cancer Prev Res (Phila) 2017 Feb;10(2):124-132
Major Program(s) or Research Group(s): Chemopreventive Agent DevelopmentProstate and Urologic Cancer
PubMed ID: 27993834
PMC ID: PMC5687250

Blood and lung microRNAs as biomarkers of pulmonary tumorigenesis in cigarette smoke-exposed mice.

Izzotti A,  Balansky R,  Ganchev G,  Iltcheva M,  Longobardi M,  Pulliero A,  Geretto M,  Micale RT,  La Maestra S,  Miller MS,  Steele VE,  De Flora S
Oncotarget 2016 Dec 20;7(51):84758-84774
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 27713172
PMC ID: PMC5341294

Interactions between ethanol and cigarette smoke in a mouse lung carcinogenesis model.

Balansky R,  Ganchev G,  Iltcheva M,  Nikolov M,  La Maestra S,  Micale RT,  Steele VE,  De Flora S
Toxicology 2016 Dec 12;373:54-62
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 27840117
PMC ID: not available

Potentiating NK cell activity by combination of Rosuvastatin and Difluoromethylornithine for effective chemopreventive efficacy against Colon Cancer.

Janakiram NB,  Mohammed A,  Bryant T,  Zhang Y,  Brewer M,  Duff A,  Biddick L,  Singh A,  Lightfoot S,  Steele VE,  Rao CV
Sci Rep 2016 Nov 14;6:37046
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 27841323
PMC ID: PMC5107958

Epidermal growth factor receptor derived peptide vaccination to prevent lung adenocarcinoma formation: An in vivo study in a murine model of EGFR mutant lung cancer.

Ebben JD,  Lubet RA,  Gad E,  Disis ML,  You M
Mol Carcinog 2016 Nov;55(11):1517-1525
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 26346412
PMC ID: PMC6019616

Pancreatic Cancer Chemoprevention Translational Workshop: Meeting Report.

Miller MS,  Allen P,  Brentnall TA,  Goggins M,  Hruban RH,  Petersen GM,  Rao CV,  Whitcomb DC,  Brand RE,  Chari ST,  Klein AP,  Lubman DM,  Rhim AD,  Simeone DM,  Wolpin BM,  Umar A,  Srivastava S,  Steele VE,  Rinaudo JA
Pancreas 2016 Sep;45(8):1080-91
Major Program(s) or Research Group(s): Chemopreventive Agent DevelopmentCancer BiomarkersGastrointestinal and Other Cancers
PubMed ID: 27518363
PMC ID: PMC4988336

IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib.

Fernando RI,  Hamilton DH,  Dominguez C,  David JM,  McCampbell KK,  Palena C
Oncotarget 2016 Jul 5;7(27):42031-42044
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 27248176
PMC ID: PMC5173114

5MeCDDO Blocks Metabolic Activation but not Progression of Breast, Intestine, and Tongue Cancers. Is Antioxidant Response Element a Prevention Target?

Lubet RA,  Townsend R,  Clapper ML,  Juliana MM,  Steele VE,  McCormick DL,  Grubbs CJ
Cancer Prev Res (Phila) 2016 Jul;9(7):616-23
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 27150634
PMC ID: PMC4930704

The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells.

Jochems C,  Fantini M,  Fernando RI,  Kwilas AR,  Donahue RN,  Lepone LM,  Grenga I,  Kim YS,  Brechbiel MW,  Gulley JL,  Madan RA,  Heery CR,  Hodge JW,  Newton R,  Schlom J,  Tsang KY
Oncotarget 2016 Jun 21;7(25):37762-37772
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 27192116
PMC ID: PMC5122347

Mammographic Density as a Biosensor of Tamoxifen Effectiveness in Adjuvant Endocrine Treatment of Breast Cancer: Opportunities and Implications.

Mullooly M,  Pfeiffer RM,  Nyante SJ,  Heckman-Stoddard BM,  Perloff M,  Jatoi I,  Brinton LA,  Aiello Bowles EJ,  Hoover RN,  Glass A,  Berrington de Gonzalez A,  Sherman ME,  Gierach GL
J Clin Oncol 2016 Jun 20;34(18):2093-7
Major Program(s) or Research Group(s): Breast and Gynecologic CancerChemopreventive Agent Development
PubMed ID: 27022110
PMC ID: PMC4962703

Selective inhibition by aspirin and naproxen of mainstream cigarette smoke-induced genotoxicity and lung tumors in female mice.

Balansky R,  Ganchev G,  Iltcheva M,  Micale RT,  La Maestra S,  D'Oria C,  Steele VE,  De Flora S
Arch Toxicol 2016 May;90(5):1251-60
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 26104855
PMC ID: not available

Symptoms and QOL as Predictors of Chemoprevention Adherence in NRG Oncology/NSABP Trial P-1.

Land SR,  Walcott FL,  Liu Q,  Wickerham DL,  Costantino JP,  Ganz PA
J Natl Cancer Inst 2016 Apr;108(4)
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 26615179
PMC ID: PMC4675829
Clinical Trials: Breast Cancer Prevention Trial (BCPT)

Global Mortality Impact of the 1957-1959 Influenza Pandemic.

Viboud C,  Simonsen L,  Fuentes R,  Flores J,  Miller MA,  Chowell G
J Infect Dis 2016 Mar 1;213(5):738-45
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 26908781
PMC ID: PMC4747626

Pharmacological Modulation of Lung Carcinogenesis in Smokers: Preclinical and Clinical Evidence.

De Flora S,  Ganchev G,  Iltcheva M,  La Maestra S,  Micale RT,  Steele VE,  Balansky R
Trends Pharmacol Sci 2016 Feb;37(2):120-142
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 26726119
PMC ID: PMC4728041

Introduction: Cancer chemoprevention and its context.

Dunn BK,  Umar A,  Richmond E
Semin Oncol 2016 Feb;43(1):19-21
Major Program(s) or Research Group(s): Chemopreventive Agent DevelopmentGastrointestinal and Other Cancers
PubMed ID: 26970121
PMC ID: PMC5166611

Repurposing old drugs to chemoprevention: the case of metformin.

Heckman-Stoddard BM,  Gandini S,  Puntoni M,  Dunn BK,  DeCensi A,  Szabo E
Semin Oncol 2016 Feb;43(1):123-133
Major Program(s) or Research Group(s): Breast and Gynecologic CancerChemopreventive Agent DevelopmentLung and Upper Aerodigestive Cancer
PubMed ID: 26970131
PMC ID: PMC4789107

Double-Blind, Randomized Trial of Alternative Letrozole Dosing Regimens in Postmenopausal Women with Increased Breast Cancer Risk.

López AM,  Pruthi S,  Boughey JC,  Perloff M,  Hsu CH,  Lang JE,  Ley M,  Frank D,  Taverna JA,  Chow HH
Cancer Prev Res (Phila) 2016 Feb;9(2):142-8
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 26667449
PMC ID: PMC4740217

The promise of omics-based approaches to cancer prevention.

Meerzaman D,  Dunn BK,  Lee M,  Chen Q,  Yan C,  Ross S
Semin Oncol 2016 Feb;43(1):36-48
Major Program(s) or Research Group(s): Chemopreventive Agent DevelopmentNutritional Science
PubMed ID: 26970123
PMC ID: not available

The National Cancer Institute's PREVENT Cancer Preclinical Drug Development Program: overview, current projects, animal models, agent development strategies, and molecular targets.

Shoemaker RH,  Suen CS,  Holmes CA,  Fay JR,  Steele VE
Semin Oncol 2016 Feb;43(1):189-197
Major Program(s) or Research Group(s): Chemopreventive Agent DevelopmentProstate and Urologic Cancer
PubMed ID: 26970137
PMC ID: PMC4789768